Weakness in Viking Therapeutics (SYM: VKTX) is an opportunity.
For one, its VK2735 obesity treatment is that trial results show it’s outperforming other products already on the market.
As noted by Seeking Alpha, “Semaglutide (Wegovy) only showed an 8% loss after 20 weeks, while tirzepatide (Zepbound) took significantly longer to reach a larger weight loss. According to a new study, the weight losses from these GLP-1s on the market was far lower than the Viking Therapeutics drug candidate.”
With exemplary results like that, Viking Therapeutics could have a potential blockbuster hit on its hands. Plus, the company said the oral form of VK2735 helped patients lose about 3.3% of body weight after 28 days in Phase 1 trials.
Two, Goldman Sachs just raised its obesity treatment market estimates from $100 billion to $130 billion. “The estimate was revised as the firm projects the number of Americans on anti-obesity drugs could reach ~19M by 2030, up from its previous estimate of ~15M. This indicates a ~17% market penetration among U.S. adults,” as noted by Seeking Alpha.
